Myelomatous pleural effusion involvement in 23 patients with multiple myeloma: A single-center clinical analysis.
We investigated the treatment and prognosis of pleural effusion (PE) in multiple myeloma (MM) patients. From June 2005 to December 2013, 296 MM patients participated in this study. There were 23 PE patients, including 11 men and 12 women, with a median age of 56.8 years (range 37-68 years). A diagnosis of PE was based on physical examination, chest X-ray or computed tomography, and pleural fluid analysis. All patients demonstrated myeloma cells in the pleural fluid, and six patients were positive for PE M protein. PE patients received bortezomib combined with other drugs. Only one patient demonstrated a complete response; 10 patients showed partial responses, and 12 patients developed progressive disease and died. MM linked with myelomatous PE is associated with a poor prognosis. Myelomatous PE is likely a late manifestation of the natural history of MM or an expression of the aggressive behavior of the disease.
Department of Hematology, Beijing Chao-Yang Hospital, Capital Medical University Beijing, China.
Yuping
Y
Zhong
Department of Hematology, Beijing Chao-Yang Hospital, Capital Medical University Beijing, China.
Jiajia
J
Zhang
Department of Health, Beijing Friendship Hospital, Capital Medical University Beijing, China.
Huan
H
Wang
Bortezomib; multiple myeloma; myelomatous pleural effusion; prognosis